Researchers have identified a promising new treatment strategy for liver fibrosis, a chronic condition that can lead to cirrhosis and liver cancer, by combining two well-known drugs. Preliminary findings suggest that using silybin together with carvedilol produces a powerful synergistic effect significantly stronger than either drug alone, against the cellular processes that drive scar tissue formation in the liver.